Understanding how a specific receptor affects bladder cancer treatment responses and side effects
The role of AHR in modulatingimmunotherapy response and adverse events in bladder cancer
This study is looking at how a specific protein in bladder cancer might affect how well some patients respond to certain treatments and why some people have side effects or their cancer grows faster after treatment, with the goal of finding ways to help more patients get better care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Van Andel Research Institute NIH-funded |
| Lab location | 1 site (Grand Rapids, United States) |
| Project ID | NIH-11014334 on NIH RePORTER |
What this research studies
This research investigates the role of the aryl hydrocarbon receptor (AHR) in bladder cancer, particularly how it influences responses to immune checkpoint inhibitors (ICIs) and the occurrence of adverse events. The study aims to identify why only a subset of patients benefit from ICIs and why some experience rapid tumor growth after treatment. By analyzing RNA and protein expression in bladder tumors, researchers hope to uncover mechanisms that could predict treatment outcomes and improve patient care. The findings could lead to better strategies for managing bladder cancer and its treatment-related complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer who are considering or currently undergoing immune checkpoint inhibitor therapy.
Not a fit: Patients with bladder cancer who are not eligible for immune checkpoint inhibitors or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for bladder cancer patients, enhancing their response to immunotherapy and reducing adverse effects.
How similar studies have performed: Previous research has shown promising results in understanding the role of immune-related adverse events in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Grand Rapids, United States
- Van Andel Research Institute — Grand Rapids, United States (Active)
Researchers
- Principal investigator: Jang, Hyo Sik — Van Andel Research Institute
- Study coordinator: Jang, Hyo Sik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.